Index

accelerated aging, 79, 138, 214, 243
Accountable Care Organizations (ACOs), 21
ACHIEVE program, 182–83
active coping, 201, 203
ADAPT-ITT method, 170
Adult Protective Services, 227
adversity, lifelong experience of, 204–6
Affordable Care Act (ACA), 22, 230
African-Americans psychotic symptoms, 27
schizophrenics in nursing homes, 18
age
nursing home schizophrenia residents, 18
quality of life and, 123
age of exposure/outcomes, 2
aging. See also late life psychosis; late life schizophrenia
accelerated, 79, 138, 214, 243
across cultures, 219
antipsychotic related movement disorders and, 61–63
brain, and schizophrenia, 56
caregivers, 192–93
metabolic syndrome and, 63–64
non-uniformity of, 200
pharmacodynamics and, 157
pharmacokinetics and, 157
response to antipsychotics, 146
schizophrenia and, 55, 63–64
schizophrenia, biomarkers in, 58–60
successful, 96, 101, 124
aging individuals with schizophrenia (AIWS).
See also late life schizophrenia
aging-out, caregivers, 197
agitation, 30
Alzheimer’s disease
cognitive decline, 70
psychotic symptoms, 33
VBR measure, 55
amotivation, 114
antipsychotics, 35, 130
antipsychotics, 147
antidepressants with, 130
bipolar disorder and, 40
cancer and, 86
cardiovascular disease and, 84, 161
dementia and, 34–35, 160
diabetes and, 83
dosing of, 161–62
drug–drug interactions, 159, 160
effects of long term exposure, 60
life expectancy and, 224
maximising compliance, 162
metabolic problems with, 21
mortality risk, 34
movement disorders and, 61–63
older adult studies, 148
public policy issues, 229
RCTs, 244
preventing/minimizing medication, 162
respiratory diseases and, 82
serious side effects and safety concerns, 160–61
side effects, 157–60, 205, 215, 223
treatment, 37
treatment, first line of, 146–47
APA guidelines, dementia treatment, 33
APOE epsilon-4, 58
aripiprazole, 35, 37, 155
dosing, 162
asenapine, 156, 159
Assertive Community Treatment (ACT), 142, 231
Assistant Secretary DHSS, 234
Assisted Outpatient Treatment (AOT), 195
auditory hallucinations, 33
autoimmune disease, 50
avoidant (passive) coping, 201, 203
avoiding disease and disability domain, 99, 100
Ayurvedic medicine, 216
Beautiful Mind, A (movie), 113
Beers Criteria, 160
behavioral tailoring, 172
biomarkers, 3
aging in schizophrenia, 58–60
bipolar disorder, 39–40, 83
birth cohort, 3
body mass index (BMI), 180, 181
brain aging, schizophrenia, 56
breast cancer, 86
brief psychotic disorder, 31
bronchitis, 82
Calgary depression rating scale (CDRS), 131
Camberwell Assessment of Need for the Elderly (CAN), 137
cancer, 85–86, 89
incidence rates, 85
mortality risk, 85
cancer screening gaps, 86
carbamazepine, 159
Cardinal Needs Schedule, 137
cardiovascular disease, 58, 63, 83–84
antipsychotics and, 84, 161
mortality rates, 83, 89, 139
prevalence rates, 84
caregivers, 190–98, 224, 245.
See also families
aging, research findings on, 192–93
aging-out of, 197
agreeable patient, 190
Assisted Outpatient Treatment, 195
dementia and, 33, 34
developing countries, 214–15, 245
difficult and violent patient, 191
family support, 233
international picture, 195–96
living with family, 227
non-assaultive crises, 191
parental, 192–93
planning for the future, 193, 194
psychological costs, 192
services assisting, 194
sibling, 194
spousal, 194
Carers’ Trust, 197
case/care management, 233
case–control studies, 1, 3, 8, 82
catatonia, 27
catechol-O-methyltransferase (COMT), 57
CATIE study, 84, 147
CCR5 gene, 50
Center for Epidemiologic Studies - Depression Scale (CESD), 98
cerebrovascular risk score, 39
China
caregivers in, 195, 214
new technologies, 218
chlorpromazine, 61, 148
cholinesterase inhibitors, 34
Chronic Disease Self-Management Program (CDSMP), 170, 171, 184
chronic obstructive pulmonary disease (COPD), 82
CITAD trial, 35
citalopram, 35, 72, 131
clinical epidemiology, 28–29
clinical outcome, 2
clinical recovery, 104
clinical remission, 100, 101, 103
clinician ratings, 118
clozapine, 35, 131, 147, 148, 157
comparison drug, 150
dosing, 162
metabolic syndrome and, 63
selected studies, 149
clubhouses, 140
cognition and function, 121
domain, 100
late life schizophrenia, 72–73
Cognitive Behavioral Social Skills Training (CBSSST), 73, 114, 176–78
cognitive behavioral therapy (CBT), 176, 245
cognitive dysfunction early-onset schizophrenia, 49, 243
late-onset schizophrenia, 49
longitudinal studies, 69–71
outcome domain, 97, 98, 103
profile, in late life schizophrenia, 71–72
schizophrenia, 57, 69
VLOSLP, 49
cognitive outcome, 103
rehabilitation, 73, 245
Collaborative care models, 21, 87
co-located models, 87
colon cancer, 86
community acceptance, 231, 232
community integration, 105, 120
Community Integration Scale (CIS), 99, 100
Community Integration Scale, 99, 100
community residences, 227
community studies, 27
cognitive decline, 70
outcome in schizophrenia, 96, 99
social functioning, 118–25
community treatment needs, 135–43
assessment of, 136–37
case study, 135
domains, 138–40
meeting, 140–42
studies of, 137–38
unmet needs, 136
comorbidities, 29, 214
cancer, 85–86
cardiovascular disease, 83–84
depression, 128
diabetes, 82–83, 171
late life schizophrenia, 79–81, 88–89, 170
prevalence of, 169
respiratory disorders, 81–82
competing risks, 3
Confusion Assessment Method (CAM), 32
congruent psychotic symptoms, 39
case analysis, interviews, 202
coping skills training, 173
coping strategies, 114, 201, 203–4
chronic heart disease (CHD), 63, 83, 84, 139
cost of living adjustment, 226, 227
C-reactive protein (CRP), 50
content analysis, 195–96
cross-sectional studies, 1, 8, 21, 87, 97, 100, 105, 123
CT scanning, 55
cultural-comparative studies, 212
cytochrome P450 (CYP) enzymes, 159
data collection, 202
day care facilities, 125
daytime activities, 140, 141
De Hert, M., 88
deinstitutionalization, 15, 119, 197
delirium, 31, 30–32
behavioral symptoms, 30
motor subtypes, 32
preventative strategies, 32
timeline of change, 32
delusional disorders, 31, 38
delusions, 4, 27, 213
Alzheimer’s disease, 33
delirium, 30
dementia, 33
Alzheimer’s disease, 32–35, See also Alzheimer’s disease
antidepressants and, 35
antipsychotics and, 34–35, 160
cholinesterase inhibitors, 34
late life psychosis association, 8
non-pharmacologic approaches, 33
VLOSLP and, 49, 242
dementia praecox, 95
Dementia Rating Scale (DRS), 71, 98
depression, 128–32
outcome domain, 97, 98, 102
outcome indicator, 105
overview of symptoms, 128–29
pharmacotherapy, 130–31
psychosocial treatment, 131
quality of life and, 123, 130
social indicator scores, 119
depression, schizophrenia and, 201
Determinants of Outcome of Severe Mental Disorder (DOSMeD), 218
deutetrabenazine, 161
developing countries, 212–20
caregivers, 214–15, 245
cross-cultural differences in treatment, 215–17
future directions for research, 218–19
innovative technologies, 217–18
late life schizophrenia, 213–14, 214–15
outlook of schizophrenia, 246
schizophrenia across cultures, 212–13
diabetes, 82–83, 88, 171
mortality risk, 82
prevalence rates, 83
diet
healthy eating, 179, 180, 182
poor, 179
diffusion tensor imaging (DTI), 50
dimensional framework, DSM-5, 97–98
disease burden, 1
disorganized thinking, 27
divalproex, 39
Dixon, Lisa, 20
dopamine receptor blockade, 61, 146, 158, 159
dopamine receptors, binding, 157
DRESS syndrome, 161
drug–drug interactions, 159, 160
Druss, B.G., 170
6 "D's" disorders, 28
DSM-5, 27
bipolar disorder, 39
delusional disorder, 38
dementia, 33
dimensional framework, 97–98
dimensionless approach, 243
psychosis symptom severity, 97
psychosis with MDD, 39
psychotic disorders, 7
schizophrenia diagnosis, 36
schizophrenia subtypes, 47
social functioning, 117
subsyndromal depression, 129
duration of exposures, 2
early-onset schizophrenia, 36, 51
cognitive defects, 49, 243
demographics, 47
neuropathology/heritability, 50
inflammation and, 50
neuropathology/neuroimaging, 49
positive and negative symptoms, 48
ECT (electroconvulsive therapy), 39, 162
emotional management, 170
genetics, 170
engagement with life domain, 129
environmental needs, 138
Epidemiologic Catchment Area (ECA) study, 14
epidemiology, 1–2, 27–29
clinical epidemiology, 28–29
defining psychosis in studies, 3–5
late life psychosis, 5–8
late life schizophrenia, 13–15
observational studies, 1, 2–3
essence of life, schizophrenia as, 203
estrogen, 48
estrogen theory, 48
ethnicity
cancer, 85
psychotic symptoms, 27
schizophrenia hospital populations, 16
schizophrenics in nursing homes, 18
treatment problems and, 229
executive dysfunction, 71
exercise. See physical activity
extrapyramidal side effects (EPS), 62, 147, 157
families
dementia and, 33
living with, 227
rejection by, 205
substitute, 208
family psychoeducation (FPE), 197
family support, 192, 233
FDA black box warning, 34, 161, 229
financing, 22–23
care in developing countries, 215
income supports, 226
meeting needs, 142
nursing homes, 232
treatment, 230
first generation antipsychotics, 34, 62, 147
older adults, 147
treatment cost, 157
first line of treatment, 146–47
fluphenazine, 147, 148, 159
food stamps, 226
fractional anisotropy, 50
Framingham study, 63, 84, 87
frontal lobe activity, reductions, 57
Functional Adaptation Skills Training (FAST), 175–76
functional MRI (fMRI), 57
funding. See financing
gender
caregivers and, 192, 193
onset of schizophrenia and, 47
Index

252

risk factors for late life psychosis, 6
social functioning and, 122
genetics, schizophrenia, through life, 57–58
Geriatric Depression Score (GDS), 129
GERI-BD trial, 39
globalization, 246
Granholm, E., 177
growth, in late life schizophrenia, 206–8
guns, access to, 225
hallucinations, 4, 27, 213
auditory, 33
delirium, 30
dementia, 33
visual, 33, 212
haloperidol, 147, 148
Hamilton Depression Rating Scale, 129, 131
Health and Recovery Peer (HARP), 170–71, 184
health care registers, 86–88, 89
Health Homes, 21, 233
health professionals, shortage of, 246
health promotion models, 179–83, 185
ACHIEVE, 182–83
InSHAPE, 180–81
STRIDE, 179–80
Healthcare Cost and Utilization Project (HCUP), 16
healthy eating, 179, 180, 182
Helping Older People Experience Success (HOPES), 174–75, 184
hepatic function, 159
herbal supplements, 159
heterogeneity of course, 106
high cognitive and physical function domain, 100
HIPAA rules, 192
HIV/AIDS, 225
homelessness, 225, 226
hospital records, 5
hospitalization, 82, 205
long-term, 228
hospitals, 16
characteristics of discharges from, 17
housing, 237
housing costs, 226, 227
housing issues, 226–28
housing programs, 223
hs-CRP biomarker, 58, 244
5HT2A receptors, 157
hyperactive delirium, 32
hypoactive delirium, 32
hypoactive/hyperactive delirium, 32
IL-6 biomarker, 59
illness self-management, 170, 184
HARP program, 170–71, 184
I-IMR program, 172–73, 184
TTIM program, 171–72, 184
income supports, 226
incongruent psychotic symptoms, 39
independent living, 99, 227
India, 196, 213, 216
Individual Placement and Support (IPS), 114
individualized care, 246
inflammation, 50
neuroinflammation, 63
information gathering, 4–5
unmet need, 139
information processing impairments, 71
inpatient sector, 15–16
inpatient treatment, 228
InSHAPE program, 180–81
institutionalization, 70
cognitive decline and, 70
worsening of symptoms, 214
integrated care, 229
Integrated-Illness Management and Recovery (I-IMR), 172–73, 184
International Late-Onset Schizophrenia Group, 47
International Pilot Study of Schizophrenia (IPSS), 218
International Study of Schizophrenia (ISoS), 218
Iran, caregivers in, 196
isolation. See social isolation
jails, 227, 228
Kinect for Xbox 360 game system, 183
Kraepelin, E., 95
lack of insight, 4
late life psychosis, 146, See also psychosis
antipsychotic studies, 148
assessment and diagnosis, 27–30, 30–41
dementia association, 8
diagnosis, comorbidities, 29
differential diagnosis, 30
epidemiology of, 5–8, 27–29
examination and laboratory assessment, 29–30
first generation antipsychotics, 147
incidence of, 6
mortality rates, 8
prevalence of, 5, 7, 28
risk factors, 6, 28, 29
second generation antipsychotics, 157
late life schizophrenia, 13, 200, 242–48. See also schizophrenia
cancer and, 85–86, 89
cardiovascular disease and, 83–84, 89
clinical and social needs, 246
cognition and function in, 72–73
community needs. See community treatment needs
comorbidities, 79–81, 88–89, 170
depression in. See depression
developing countries. See developing countries
diabetes and, 82–83, 88, 171
diagnosis, 242
ECT, 162
experience of growth, 206–8
financing, 22–23
future research needs, 235–36
Index

253

health care utilization, 86–88, 89

health promotion models, 179–83, 185

illness self-management, 170–73, 184

inpatient sector, 15–16

model programs/ interventions in the future, 183–85

morbidity rates, 20

non-pharmacologic treatment, 38

nursing homes, 17–20

outcomes. See outcome in schizophrenia

outpatient care, 20

physical health care, 20–22

prevalence, trends in, 13–15, 169

psychosocial rehabilitation, 173–78, 184

respiratory disorders and, 81–82, 88

social functioning. See social functioning

subjective accounts of. See subjective accounts treatment, 37

late-onset schizophrenia, 31, 36, 37, 47, 51

cognitive deficits, 49

demographics, 47

developing countries, 213
diagnostic status, 47

genetics/heritability, 50

inflammation and, 50

neuropathology/ neuroimaging, 49–50

positive and negative symptoms, 48–49

sensory deficits, 50

treatment, 51

Lewy body disease

antipsychotic side effects, 35

psychotic symptoms, 33

life expectancy

psychosis, 223, 224

public policy goal, 236

schizophrenia, 79, 169

life review, 209

lithium, 39

living with family, 227

longitudinal studies, 1, 3

cognitive functioning, 69–71

outcome domains, 102–5

predictors and trajectories, 103

loxapine, 148, 157

lung cancer, 85, 86

lurasidone, 156, 159

major depressive disorder (MDD), 38–39

major depressive episodes, 129

major neurocognitive disorder, 31

major vascular neurocognitive disorder, 33

mania, antipsychotic treatment, 40

Medicaid, 22, 230

funding nursing homes, 22, 232

restructuring, 237

medical disorders. See specific medical disorder

medical management, 170

Medicare, 20, 22, 230

Part D, 22

restructuring, 237

Medicare Improvements for Patients and Providers Act (MIPPA), 23

memantine, 34

memory deficits, 71

men. See gender

Mental Health Parity and Addiction Equity Act of 2008, 22

mental health services

drift to long term care, 232

meeting needs, 140, 141

shortage of providers, 215

unengagement with, 142

mental illness. See specific mental illness

mentors, 207

Meriden Family Programme, 197

Met allele, 57

met needs, 136

metabolic syndrome, 61, 63–64

microglial activation, 60

mild neurocognitive disorder, 31

mind cure, 112

Mini-Mental State Examination (MMSE), 70, 71

Minimum Data Set (MDS), 18

mirror sign, 33

misidentification, 33

mobile technologies, 87, 185, 217, 248

model programs

ACHIEVE, 182–83

FAST, 175–76

future directions/ recommendations, 183–85

HARP, 170–71, 184

health promotion, 179–83, 185

HOPES, 174–75, 184

I-IMR, 172–73, 184

illness self-management, 170–73, 184

InSHAPE, 180–81

PEDAL, 176

psychosocial rehabilitation, 173–78, 184

STRIDE, 179–80

TTIM, 171–72, 184

Moos’ Ecosystem Model, 99

Morse’s principles, 202

mortality

antipsychotics and, 34

cancer, 83, 89, 139

caregivers and, 193

dementia patients, 161

diabetes, 82

drug–drug interactions and, 159

late life psychosis, 8

late life schizophrenia, 79–81

respiratory disorders, 81

risk, 85

schizophrenia, 6, 20, 79

mortality gap, 224–26, 236

motivation, unmet needs and, 143

movement disorders, antipsychotic related, 61–63

MRI scanning

fMRI, 57

onset of schizophrenia and, 49

schizophrenia, 56
Nash, John, 113, 190
National Alliance on Mental Illness (NAMI), 192, 193, 195, 196, 198
National Comorbidity Survey Replication (NCS-R), 14, 38, 39
National Inpatient Sample (NIS), 16
National Institute of Mental Health (NIMH), 59, 235
need domains, 138–40
environmental, 138
physical, 138
psychological, 139–40
social, 140
needs
assessment, 136–37
met, 136
unmet. See unmet needs
negative symptom domains, 97, 98
neurocognitive disorders, 28. See also dementia
early-onset schizophrenia and, 243
major, 31
major vascular, 33
neuroimaging
early and late onset schizophrenia, 49
functional, 56
schizophrenia, 55–63
neuroinflammation, 63
neuroleptic malignant syndrome (NMS), 161
neuropathology
early and late onset schizophrenia, 49
schizophrenia, 60
New Club, The, 141–42
non-affective psychoses (NAP), 14
non-motor delirium, 32
non-primary diagnosis of schizophrenia
hospital populations, 16
normalization, 207, 208
nursing homes, 17–20
cognitive decline and, 70
financing through Medicaid, 22
funding, 232
mental illness admissions, 169
polypharmacy interactions, 159
resident characteristics, 19
obesity, 179, 180, 181, 182, 224
neuroinflammation and, 63
OBRA-87 legislation, 17, 18
observational epidemiology studies, 1, 2–3
observer-based ratings, 117, 118
olanzapine, 35, 37
cardiovascular risks, 84
cognition study, 72
correlation of indicators over time, 105
developing countries, 246
DSM-5 dimensional framework, 97–98
heterogeneity of course, 106
historical rates, 95
methods, 96
paradoxical aging and, 106
recovery prospects, 99–101
trajectories and risk factors, 101, 102–5
uniqueness of symptom domains, 98
outpatient care, 20, 228
outreach programs, 87, 193, 216, 231
paliperidone, 155, 159
paradoxical aging, 96, 106
paraphrenia, diagnostic criteria, 69
parental caregivers, 192
research findings on, 192–93
parkinsonian symptoms, 62
Parkinson's disease, 33
antipsychotic side effects, 35
Partners in Care, 197
Patient Centered Medical Home (PCMH), 21
Patient Outcomes Research Team (PORT), 231
Patient Protection and Affordable Care Act (ACA), 22, 230
Patterson, T.L., 175, 176
PEDAL program, 176
personal accounts. See subjective accounts
pharmacodynamics, and aging, 157
pharmacokinetics, and aging, 157
physical activity increasing, 180
low levels, 179
physical activity programs, 178, 181, 182, 232
videogame-based, 183
physical health care, 20–21
physical integration, 99
physical needs, 138
pidelavasin, 35, 244
PLAN program, 196
pneumonia, 82
police interventions, 191, 195
polygenic influences, cognition, 57, 58
polygenic risk score, 58
polypharmacy, 159
Positive and Negative Syndrome Scale (PANSS), 98, 99
positive psychiatry, 114
defining, 112
historical background, 112
interventions in schizophrenia, 114
outcome in schizophrenia, 113
psychosocial factors, 113
positive symptom domains, 97, 98
positron emission tomography (PET), 57
posttraumatic stress disorder (PTSD), 139, 140
potential life lost, 80
PREMIER lifestyle intervention, 179
prescribing cascade, 159
Primary and Behavioral Health Care Integration (PBHCI), 87
Index

Primary Care Access, Referral, and Evaluation (PCARE), 87
primary diagnosis of schizophrenia hospital populations, 16
primary psychiatric disorders, 28, 146
examination and assessment, 29
prisons, 227, 228
Program of Assertive Community Treatment (PACT), 195
prolactin, 86
psychiatric hospitals, 15–16
psychoeducation, 172
psychological integration, 99
psychological needs, 139–40
psychosis. See also late life psychosis; schizophrenia crisis situations, 191
defining, in epidemiological studies, 3–5
dementia-related. See dementia DSM criteria, 7
gathering information on symptoms, 4–5
information from health care registers, 5
life expectancy, 223, 224
measurement vs. evaluation, 3
observational epidemiological literature, 2–3
primary care, lack of, 21
recovery model, 208
recovery-oriented rehabilitation, 231
relapse prevention training, 172
religion, 232
remission in schizophrenia, 140, 173–78, 184
CBSST, 176–78
FAST program, 175–76
HOPES program, 174–75, 184
models in review, 178
PEDAL program, 176
psychotherapy, 229
public policy issues, 223–37
coordination of systems and leadership, 234
future research, 235–36
housing and residential care, 226–28, 237
income supports, 226
mortality gap and, 224–26, 236
psychosocial interventions, 231–34
treatment issues, 228–31
workforce challenges, 234
QTc prolongation, 159
quality of life, 123–24, 207, 224
depression and, 123, 130
public policy goal, 236
subjective, 123
quetiapine, 35, 37, 159
cardiovascular risk, 84
dosing, 162
selected studies, 154
ritodrine, 162
randomized controlled trials (RCTs), 244, 245, 246
reciprocity, and caring, 190
recovery model, 96, 208
recovery prospects in late life schizophrenia, 99–101
recovery-oriented rehabilitation, 231
rehabilitation
psychosocial. See also social functioning
crisis situations, 191
positive, 113
psychosocial interventions, 73, 131, 162, 172, 231–34
access to mainstream society, 231
research on, 236
psychosocial models of care, 87
psychosocial rehabilitation, 140, 173–78, 184
CBSST, 176–78
FAST program, 175–76
residential care, 226–28, 237
drift to, 232
payment for, 226
respiratory disorders, 81–82, 88
mortality risk, 81
prevalence rates, 82
revascularization, 84
reverse-integrated models, 87
risperidone, 35, 37, 147, 157
cognition study, 72
dosage, 152
long-acting injectable, 152
selected studies, 150
role management, 170
Sajatovic, M., 171, 172
Saks, Elyn, 190
SAMHSA, 234
SCALE acronym, 177
scatter beds, 16
schizoffective disorder, 31, 38
schizophrenia, 31, 32
See also early-onset schizophrenia; late life schizophrenia; late-onset schizophrenia; very-late-onset schizophrenia-like psychosis
across cultures, 212–13
adverse symptoms, 205
age-related changes, 55
biomarkers of aging, 58–60
cognitive dysfunction. See cognitive dysfunction
comorbidities in nursing homes, 18
cross-cultural differences in treatment, 213–17
diagnosis, 36–37
direct and indirect costs of, 13
essential of life, 203
functional imaging, 56
genetics, through life, 57–58
late life psychosis association, 8
life expectancy, 79, 169
living life whilst managing, 203
metabolic syndrome and aging, 63–64
mortality rates, 6, 20, 79
neuroimaging in, 55–56
neuropathology, 60

© in this web service Cambridge University Press
https://www.cambridge.org
cognitive defects, 49
dementia and, 242
demographics, 47
positive and negative symptoms, 48
treatment, 51
Veterans' Administration (VA), 230, 237
videogame-based physical activity program, 183
violent patient, 191
visual hallucinations, 33, 212
visuospatial impairments, 71
VLOSLP. See very-late-onset schizophrenia-like psychosis
wellness programs, 232
white matter changes, 56, 57
women. See gender
workforce challenges, 234
workforce, selection and training, 142
World Health Organization (WHO), 27, 212, 215
Wu, E.Q., 14
Yarborough, B.J., 179
ziprasidone, 155, 159
dosing, 162